Variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and vaccine effectiveness

SRV Tulimilli, S Dallavalasa, CG Basavaraju… - Vaccines, 2022 - mdpi.com
The incidence and death toll due to SARS-CoV-2 infection varied time-to-time; and
depended on several factors, including severity (viral load), immune status, age, gender …

What makes SARS‐CoV‐2 unique? Focusing on the spike protein

J Qian, S Zhang, F Wang, J Li… - Cell Biology …, 2024 - Wiley Online Library
Severe acute respiratory syndrome‐related coronavirus 2 (SARS‐CoV‐2) seriously
threatens public health and safety. Genetic variants determine the expression of SARS‐CoV …

Immunodominant SARS‐CoV‐2‐specific CD4+ and CD8+ T‐cell responses elicited by inactivated vaccines in healthy adults

J Ning, Q Wang, Y Chen, T He, F Zhang… - Journal of Medical …, 2023 - Wiley Online Library
Safety profiles and humoral responses to inactivated severe acute respiratory syndrome
coronavirus 2 (SARS‐CoV‐2) vaccines have been previously assessed, but cellular immune …

COVID-19 Incidence Proportion as a Function of Regional Testing Strategy, Vaccination Coverage, and Vaccine Type

AA Totolian, VS Smirnov, AA Krasnov, ES Ramsay… - Viruses, 2023 - mdpi.com
Introduction: The COVID-19 pandemic has become a serious challenge for humanity almost
everywhere globally. Despite active vaccination around the world, the incidence proportion …

[HTML][HTML] COVID-19 case numbers as a function of regional testing strategy, vaccination coverage, and vaccine type

AA Totolian, VS Smirnov, AA Krasnov, ES Ramsay… - 2022 - europepmc.org
Results: After formation of the final data set (including 53 countries), it turned out that
reported COVID-19 case numbers correlated most strongly with testing coverage and the …

The protection quest is a primary key to sharing the neutralizing antibody response to cover against all emerging VOCs based on BIV1-CovIran studies

M Shafaati, K Bagherzadeh, M Lotfinia, H Karimi… - Heliyon, 2023 - cell.com
Over time, the antigenic evolution of emerging variants of SARS-CoV-2 has demanded the
development of potential protective vaccines. Administration of additional doses of current …

Prediction of hospitalization time probability for COVID-19 patients with statistical and machine learning methods using blood parameters

K Motarjem, M Behzadifard, S Ramazi… - Annals of Medicine …, 2024 - journals.lww.com
Objectives: Coronavirus disease 2019 (COVID-19) may induce life-threatening
complications and lead to death in the patients. Method: The aim of this study was to …

[HTML][HTML] Stability of Neutralizing Antibody of PastoCoAd Vaccine Candidates against a Variant of Concern of SARS-CoV-2 in Animal Models

M Panahi, A Teimoori, S Esmaeili… - Iranian biomedical …, 2024 - pmc.ncbi.nlm.nih.gov
Background: Since the beginning of the SARS-CoV-2 pandemic, there have been mutations
caused by new SARS-CoV-2 variants, such as Alpha, Beta, Gamma, Delta, and Omicron …

COVID-19 vaccines and a perspective on Africa

A Mantovani, M Rescigno, G Forni, F Tognon… - Trends in …, 2023 - cell.com
Vaccines have dramatically changed the COVID-19 pandemic. Over 30 vaccines that were
developed on four main platforms are currently being used globally, but a deep dissection of …

Immunogenicity and effectiveness of the Sinopharm BIBP COVID-19 inactivated vaccine in people living with HIV: A case-control study in Omicron era

AZ Dehnavi, SAD Manshadi, SAS Alinaghi… - Medical Research …, 2024 - esmed.org
There is limited information about COVID-19 vaccines in people living with HIV (PLWH). We
aimed to compare the immunogenicity and effectiveness of the Sinopharm BIBP COVID-19 …